Fig. 8: High UHRF1 expression is predictive of poor survival in human KRAS mutant lung adenocarcinoma.

a Kaplan–Meier plots of disease specific survival (DSS) in the lung adenocarcinoma (LUAD) cohort from TCGA. Blue solid line represents the normal UHRF1 expression group (expression <75th percentile) and red solid line represents the high UHRF1 expression group ( > 75th percentile). Left - KRAS mutant patients, HR = 2.85, p-value = 0.01; middle - KRAS wild-type patients, HR = 1.53, p-value = 0.092, right – distribution of UHRF1 log2 (CPM) counts by sample and color-coded by high or low group assignments based on 75th percentile. Two-tailed Student’s t test used to calculate the p-value. b Left pie chart – Correlation between UHRF1 expression and TSG expression. Right pie chart – Correlation between KRAS expression and expression of 323 TSGs (out of 450 TSGs anticorrelated with UHRF1) which significantly correlate with KRAS expression. Only significantly correlated TSGs (FDR < 0.05) were plotted for both datasets. Rho Direction: TSGs negatively (neg) or positively (pos) correlated with UHRF1 or KRAS expression. c Four examples of TSGs negatively correlated with UHRF1 in the LUAD dataset. Expression represented in log2 (CPM). Correlation coefficient and p-value computed using Spearman rank correlation test. Linear trend lines were generated using a linear model, shaded confidence regions represent CI = 0.95. d Kaplan–Meier plots of overall survival (OS) in the lung adenocarcinoma (LUAD) cohort from TCGA. Patient samples were divided based on the expression of 16 TSGs whose expression is anticorrelated with both UHRF1 expression and KRAS expression in the LUAD dataset samples. Blue solid line represents normal expression of the 16 TSGs (expression <75th percentile) and red solid line represents high expression (>75th percentile). Left - KRAS mutant patients, HR = 0.172, p-value < 0.001; right - KRAS wild-type patients, HR = 0.794, p-value = 0.357.